ClinicalTrials.gg
CompletedNCT03446885Updated Jun 24, 2021Results posted

Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD

A Phase 4 interventional study of Lisdexamfetamine Dimesylate 40 MG and Placebo in Attention Deficit Disorder With Hyperactivity, sponsored by Gregory Fabiano. Completed at 1 site in United States. Open to participants aged 16 Years to 25 Years. Per ClinicalTrials.gov, last updated 2021-06-24.

Sponsored by Gregory Fabiano · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
16 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
42nd of 51
22 · median 48
Started
2018
with 2 others
Phase 4
23 of 51
none open now
Registered
47th of 51
by date

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 42nd largest by enrollment, is one of 3 that started in 2018, is one of 23 in phase 4, and was the 47th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

There has been little research on the third area of impairment noted in the Diagnostic and Statistical Manual of Mental Disorders - "occupational functioning." Individuals with ADHD experience job-related impairments including a greater likelihood of being unemployed and not enrolled in school and for those that were employed they were in a lower status occupation, relative to typically-developing comparison peers. The current literature on analogue workplace settings and the effects of lisdexamfetamine dimesylate includes office-based tasks similar to school seat work. Unfortunately, this is inconsistent with the typical work environment most common for individuals with disabilities such as ADHD where food preparation is the most common job following high school. Therefore, medication effects in this type of setting, most common for individuals with ADHD entering the workforce, need to be studied. The investigators propose to study workplace behavior in an analogue work setting in a laboratory "pizza place." Individuals with ADHD will participate in an interview with a supervisor each day, have a list of deliveries that need to be managed, deal with situations that require occupational judgment and appropriate customer service, and drive to make deliveries accurately and on-time. These behaviors can be reliably assessed within the laboratory. Twenty young adults will participate in two "workdays" within a randomized, double-blind, placebo-controlled design wherein participants will be administered placebo and .3 mg/kg lisdexamfetamine dimesylate in a counter-balanced order.

03

Conditions studied

  • Attention Deficit Disorder With Hyperactivity
04

Who can participate

Ages eligible
16 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of ADHD
  • parental permission and/or teen consent/assent as appropriate
  • between 16-25 years of age
  • IQ greater than or equal to 70
  • permit or license to drive
  • ability to read and understand English

Exclusion criteria

Exclusion Criteria:

  • any medical condition that would contraindicate use of stimulant medication
  • any prior adverse response to lisdexamfetamine dimesylate or other stimulant medication
  • use of concurrent,non-stimulant psychoactive medication
  • diagnosis of schizophrenia or presence of thought disorder symptoms
  • autism spectrum disorder
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Lab visit 1

    40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.

    Drug: Lisdexamfetamine Dimesylate 40 MG · Drug: Placebo

  • Experimental
    Lab visit 2

    40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.

    Drug: Lisdexamfetamine Dimesylate 40 MG · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Ratings of Job Application Quality

    Three independent coders will review each de-identified application. Following the review of the application, coders will complete a rating form that asks them to make an overall evaluation regarding whether the person was an acceptable job candidate for an interview using a scale of 1 ("definitely not") to 5 ("definitely"). Average rating across coders will be used as the dependent measure.

    Time frame: during interventional study session, 1 day in duration

  2. Ratings of Job Interview Performance

    Three coders who are unaware of the study participant identities or group status will view the job interview videotape and completed a form. Raters will provide a rating of their overall impression of the interview behavior ranging from a score of one (Poor) to four (Outstanding). The average score of the coders will be utilized as a dependent measure.

    Time frame: during interventional study session, 1 day in duration

  3. Objective Observation of Workplace Productivity

    The dependent measures from this aspect of the study are the number of items completed correctly out of the total number of assigned items (i.e., 225). Thus, the score reflects the percentage of items correctly completed out of the 225 assigned and scores could range from 0-100.

    Time frame: during interventional study session, 1 day in duration

  4. Inattentive/Overactive Rating

    In addition to ratings of the interview performance, the rater also will complete the five-item inattentive/overactive (I/O) factor of the Iowa Conners rating scale (Atkins, Pelham, \& Licht, 1989; Loney \& Milich, 1982; Pelham, Milich, Murphy, \& Murphy, 1989). The five items are rated on a scale of Not at all (0) to Very Much (3) and the sum of these items represents the score. The dependent measure will be the score averaged across raters. Scores can range from 0-3 on each item, and the average score of the 5 items was used. Higher scores reflect greater inattentive/overactivity-related behaviors.

    Time frame: during interventional study session, 1 day in duration

07

Results

Posted Jun 24, 2021

Participant flow

Participant flow — Overall Study
MilestoneAllocated to Vyvanse FirstAllocated to Placebo First
Started1210
Completed1010
Not completed20
Withdrew: Lost to follow-up10
Withdrew: Did not complete entire visit10

Outcome measures

PrimaryRatings of Job Application Quality

Three independent coders will review each de-identified application. Following the review of the application, coders will complete a rating form that asks them to make an overall evaluation regarding whether the person was an acceptable job candidate for an interview using a scale of 1 ("definitely not") to 5 ("definitely"). Average rating across coders will be used as the dependent measure.

Time frame:
during interventional study session, 1 day in duration
Reported as:
Mean · score on a scale
Ratings of Job Application Quality
score on a scalePlaceboVyvanse
Ratings of Job Application Quality3.40 ± 1.033.56 ± 1.00
PrimaryRatings of Job Interview Performance

Three coders who are unaware of the study participant identities or group status will view the job interview videotape and completed a form. Raters will provide a rating of their overall impression of the interview behavior ranging from a score of one (Poor) to four (Outstanding). The average score of the coders will be utilized as a dependent measure.

Time frame:
during interventional study session, 1 day in duration
Reported as:
Mean · score on a scale
Ratings of Job Interview Performance
score on a scalePlaceboVyvanse
Ratings of Job Interview Performance3.17 ± .763.33 ± .91
PrimaryObjective Observation of Workplace Productivity

The dependent measures from this aspect of the study are the number of items completed correctly out of the total number of assigned items (i.e., 225). Thus, the score reflects the percentage of items correctly completed out of the 225 assigned and scores could range from 0-100.

Time frame:
during interventional study session, 1 day in duration
Reported as:
Mean · score on a scale
Objective Observation of Workplace Productivity
score on a scalePlaceboVyvanse
Objective Observation of Workplace Productivity65.60 ± 17.5568.45 ± 15.60
PrimaryInattentive/Overactive Rating

In addition to ratings of the interview performance, the rater also will complete the five-item inattentive/overactive (I/O) factor of the Iowa Conners rating scale (Atkins, Pelham, \& Licht, 1989; Loney \& Milich, 1982; Pelham, Milich, Murphy, \& Murphy, 1989). The five items are rated on a scale of Not at all (0) to Very Much (3) and the sum of these items represents the score. The dependent measure will be the score averaged across raters. Scores can range from 0-3 on each item, and the average score of the 5 items was used. Higher scores reflect greater inattentive/overactivity-related behaviors.

Time frame:
during interventional study session, 1 day in duration
Reported as:
Mean · score on a scale
Inattentive/Overactive Rating
score on a scalePlaceboVyvanse
Inattentive/Overactive Rating2.13 ± 1.332.01 ± 1.28

Adverse events

Collected over Each condition in the study (i.e., placebo, Vyvanse) was administered on a single day, approximately one week apart, for each participant. Adverse events were evaluated for the day of administration of each condition.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/20 (0%)0/20 (0%)0/20 (0%)
Vyvanse0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)ADHD Participant
Mean19.76 ± 2.8
Sex: Female, Male
Sex: Female, Male(Participants)ADHD Participant
Female4
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ADHD Participant
Hispanic or Latino3
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ADHD Participant
American Indian or Alaska Native1
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American3
White14
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)ADHD Participant
United States21
Currently prescribed stimulant medication
Currently prescribed stimulant medication(Participants)ADHD Participant
Count of participants14
08

Study locations

1 site
  • SUNY at Buffalo
    Buffalo, New York 14214, United States
09

References and documents

Publications

  • Gordon CT, Fabiano GA, Hulme KF, Sodano SM, Adragna M, Lim R, Stanford S, Janikowski L, Bufalo B, Rodriguez Z, Swiatek D. Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder. Exp Clin Psychopharmacol. 2021 Aug;29(4):308-318. doi: 10.1037/pha0000365. Epub 2020 Apr 16. PubMed 32297783 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2019, 10 months.

Results were first posted in Jun 2021, 2 years 4 months after primary completion.

Of 44 non-industry phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 10 months is below that.

Counting every sponsor, half of 62 studies reached it within 38 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2017
First posted
Feb 27, 2018
StartActual
Apr 1, 2018
Primary completionActual
Feb 11, 2019
CompletionActual
Aug 30, 2019
Results first posted
Jun 24, 2021
Last update
Jun 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03446885
Lead sponsor
Gregory Fabiano
Responsible party
Gregory Fabiano (Professor, State University of New York at Buffalo) — Sponsor-investigator
First posted
Feb 27, 2018
Start date
Apr 1, 2018
Primary completion
Feb 11, 2019
Completion
Aug 30, 2019
Results posted
Jun 24, 2021
Last update
Jun 24, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion